Thermo Fisher Scientific Inc (TMO)
574.61
+2.88
(+0.50%)
USD |
NYSE |
Apr 26, 13:53
Thermo Fisher Scientific Enterprise Value: 244.95B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 244.95B |
| April 24, 2024 | 247.11B |
| April 23, 2024 | 246.05B |
| April 22, 2024 | 236.05B |
| April 19, 2024 | 234.68B |
| April 18, 2024 | 233.44B |
| April 17, 2024 | 235.62B |
| April 16, 2024 | 238.40B |
| April 15, 2024 | 239.67B |
| April 12, 2024 | 242.48B |
| April 11, 2024 | 246.04B |
| April 10, 2024 | 245.71B |
| April 09, 2024 | 251.62B |
| April 08, 2024 | 247.65B |
| April 05, 2024 | 247.90B |
| April 04, 2024 | 244.53B |
| April 03, 2024 | 246.58B |
| April 02, 2024 | 244.89B |
| April 01, 2024 | 247.14B |
| March 28, 2024 | 248.57B |
| March 27, 2024 | 247.87B |
| March 26, 2024 | 243.85B |
| March 25, 2024 | 245.65B |
| March 22, 2024 | 249.29B |
| March 21, 2024 | 249.68B |
| Date | Value |
|---|---|
| March 20, 2024 | 248.13B |
| March 19, 2024 | 249.15B |
| March 18, 2024 | 248.13B |
| March 15, 2024 | 249.69B |
| March 14, 2024 | 249.98B |
| March 13, 2024 | 253.19B |
| March 12, 2024 | 254.69B |
| March 11, 2024 | 255.52B |
| March 08, 2024 | 254.82B |
| March 07, 2024 | 254.84B |
| March 06, 2024 | 252.49B |
| March 05, 2024 | 249.87B |
| March 04, 2024 | 248.73B |
| March 01, 2024 | 246.71B |
| February 29, 2024 | 244.36B |
| February 28, 2024 | 245.07B |
| February 27, 2024 | 242.83B |
| February 26, 2024 | 241.81B |
| February 23, 2024 | 242.28B |
| February 22, 2024 | 240.67B |
| February 21, 2024 | 237.76B |
| February 20, 2024 | 235.96B |
| February 16, 2024 | 235.85B |
| February 15, 2024 | 236.12B |
| February 14, 2024 | 236.01B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
117.17B
Minimum
Mar 23 2020
293.76B
Maximum
Dec 31 2021
207.07B
Average
222.78B
Median
Oct 12 2022
Enterprise Value Benchmarks
| Fonar Corp | 48.14M |
| XWELL Inc | -7.551M |
| ProPhase Labs Inc | 94.85M |
| Applied DNA Sciences Inc | 0.852M |
| Veracyte Inc | 1.246B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.63B |
| Revenue (Quarterly) | 10.89B |
| Total Expenses (Quarterly) | 8.952B |
| EPS Diluted (Quarterly) | 4.20 |
| Gross Profit Margin (Quarterly) | 40.35% |
| Profit Margin (Quarterly) | 14.97% |
| Earnings Yield | 2.69% |
| Operating Earnings Yield | 3.28% |
| Normalized Earnings Yield | 2.886 |